주식/증권 📈 긍정적

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

MarketWatch - Top Stories 2026/10/13 15:17:00 1회

요약

The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.

원문 기사 보기

관련 뉴스

Fund managers won't dump stocks for bonds until yields hit 5.9%, BofA survey says: Chart of the Day

Gold’s upside outweighs downside risks as markets face oil, France uncertainty

Kimberly-Clark wins EU conditional approval for $40B purchase of Kenvue

J&J shares down despite guidance raise as MedTech revenues disappoint

뉴스 목록으로